Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

0.9900 -0.0400 (-3.88%)

Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

An Unexpected Feat Just Sent Pliant Therapeutics Soaring More Than 50% ↗

January 23, 2023

The company has a potentially best-in-class approach to a lung condition.

Via Investor's Business Daily

US Stocks Mostly Higher; Synchrony Financial Earnings Top Views ↗

January 23, 2023

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 90 points on Monday.

Via Benzinga

Why Is Xylem (XYL) Stock Down 9% Today ↗

January 23, 2023

Xylem (XYL) stock is slipping on Monday after the company revealed plans to acquire Evoqua (AQUA) in a $7.5 billion deal.

Via InvestorPlace

Why Is Ryvyl (RVYL) Stock Is On the Move Today? ↗

January 23, 2023

Ryvyl (RVYL) stock is on the move Monday after saying its prior financial data can no longer be relied on and revealing an investigation.

Via InvestorPlace

Benzinga's Talk of the Town: Top Social Trending Stories You Need To Know ↗

January 23, 2023

What's trending on Social Media today:

Via Benzinga

Why Is Pliant Therapeutics (PLRX) Stock Up 62% Today? ↗

January 23, 2023

Pliant Therapeutics (PLRX) stock is taking off on Monday after releasing positive Phase 2a clinical trial data for bexotegrast.

Via InvestorPlace

Where Pliant Therapeutics Stands With Analysts ↗

September 01, 2022

Analysts have provided the following ratings for Pliant Therapeutics (NASDAQ:PLRX) within the last quarter:

Via Benzinga

Expert Ratings for Pliant Therapeutics ↗

August 09, 2022

Within the last quarter, Pliant Therapeutics (NASDAQ:PLRX) has observed the following analyst ratings:

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 23, 2023

Via Benzinga

Why Pliant Therapeutics Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket ↗

January 23, 2023

Gainers Jeffs' Brands Ltd (NASDAQ: JFBR) rose 76.5% to $2.70 in pre-market trading after jumping 19% on Friday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

January 23, 2023

We're starting off the week with a breakdown of the biggest pre-market stock movers traders will want to watch for Monday!

Via InvestorPlace

Pliant Therapeutics Stock Surges After Positive Data From Lead Program In Scarred Lung Disorder ↗

January 23, 2023

Pliant Therapeutics Inc (NASDAQ: PLRX) has announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with idiopathic...

Via Benzinga

Salesforce, Tesla And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

January 23, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

January 22, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

December 15, 2022

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗

December 14, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 02, 2022

Via Benzinga

Pliant Therapeutics to Participate in Upcoming Investor Conferences

November 15, 2022

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 08, 2022

From Pliant Therapeutics, Inc.

Via GlobeNewswire

3 Soaring Biotech Stocks That Could Climb Much Higher ↗

October 20, 2022

These drugmakers have bucked the overall market's downward trend this year and expectations are still high.

Via The Motley Fool

Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium

October 05, 2022

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday ↗

September 22, 2022

Gainers

Via Benzinga

Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session ↗

September 21, 2022

Gainers

Via Benzinga

Pliant Therapeutics Inc. (NASDAQ: PLRX) Climbs to New 52-Week High

September 14, 2022

Via Investor Brand Network

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

September 01, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022 ↗

September 01, 2022

Upgrades

Via Benzinga

7 Cheap Biotech Stocks to Buy Now ↗

August 03, 2022

These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector.

Via InvestorPlace

Pliant Therapeutics Secures FDA Fast Track Status For Liver Disease Drug ↗

July 21, 2022

Pliant Therapeutics (NASDAQ: PLRX) received Fast Track designation for its lead asset PLN-74809 from the U.S. Food and Drug Administration (FDA) for the potential treatment of primary sclerosing...

Via Benzinga

4 Analysts Have This to Say About Pliant Therapeutics ↗

July 20, 2022

Over the past 3 months, 4 analysts have published their opinion on Pliant Therapeutics (NASDAQ:PLRX) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.